Clinical spectrum, treatment and outcome of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease in children: a tertiary care experience

Basit Öğe Kaydı
dc.contributor.authorSerin, Hepsen Mine
dc.contributor.authorYilmaz, Sanem
dc.contributor.authorSimsek, Erdem
dc.contributor.authorKanmaz, Seda
dc.contributor.authorEraslan, Cenk
dc.contributor.authorAktan, Gul
dc.contributor.authorGokben, Sarenur
dc.date.accessioned2021-05-03T20:36:49Z
dc.date.available2021-05-03T20:36:49Z
dc.date.issued2021
dc.departmentEge Üniversitesien_US
dc.description.abstractAnti-myelin oligodendrocyte glycoprotein antibodies have been associated with a wide range of clinical presentations including monophasic and relapsing disease courses. Lack of a definitive marker for predicting further relapses and the final diagnoses complicates the clinical follow-up and treatment decisions for patients with the first episode. This study retrospectively analyzed the clinical spectrum, treatment protocols and outcome of nine children with MOG antibody-associated demyelinating disease. Diagnoses at first presentation were acute disseminated encephalomyelitis (ADEM) in six cases (67%), optic neuritis in two cases (22%), and clinically isolated syndrome in one case (11%). The disease remained monophasic in five (56%) cases. All cases with a monophasic disease course were negative for anti-MOG antibody titers in the third month. The initial diagnosis of all relapsing cases was ADEM. Three of the four cases with a relapsing disease course were available for anti-MOG antibody testing at the third month and all were positive, however, antibody titers at the sixth month were inconsistent. Cases with a relapsing disease course had no further attacks after monthly intravenous immunoglobulin treatment. Relapsing disease course is not rare in childhood MOG-antibody associated demyelinating disease. Monthly IVIG treatment may be a good alternative for the long-term treatment of relapsing cases with a low side effect profile. Anti-MOG antibody serostatus at remission periods should be interpreted cautiously. Further studies are needed to better understand and predict the clinical course of pediatric patients with MOG-antibody associated diseases.en_US
dc.identifier.doi10.1007/s13760-020-01499-9en_US
dc.identifier.endpage239en_US
dc.identifier.issn0300-9009
dc.identifier.issn2240-2993
dc.identifier.issue1en_US
dc.identifier.pmid33231843en_US
dc.identifier.startpage231en_US
dc.identifier.urihttps://doi.org/10.1007/s13760-020-01499-9
dc.identifier.urihttps://hdl.handle.net/11454/70232
dc.identifier.volume121en_US
dc.identifier.wosWOS:000592570700002en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofActa Neurologica Belgicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMyelin oligodendrocyte glycoprotein antibodyen_US
dc.subjectChildhooden_US
dc.subjectInflammatory demyelinating diseasesen_US
dc.subjectTreatmenten_US
dc.subjectOutcomeen_US
dc.titleClinical spectrum, treatment and outcome of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease in children: a tertiary care experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu